The FDA has released an advisory regarding the Novartis recall due to the mixed bottling of products. While previous reports suggested that the OTC drugs NoDoz, Excedrin, Bufferin and Gas-X had simply been mixed with each other, the FDA now is warning patients that high-powered, prescription-only opioid drugs may have found their way into Novartis OTC packaging.

The FDA said these “potent medications” include nine opioids: Opana ER, Opana, Oxymorphone, Percocet, Percodan, Endocet, Endodan, Morphine Sulfate and Zydone.

Analysts say Novartis stands to lose $560 million in sales over the next 12 months, and potentially $1.1 billion globally.

Novartis noted that Gas-X is no longer on the list of products involved in the bottling mishaps.